Drug Discovery & Development
Researchers discover potent inhibitors of SARS-CoV-2 main protease
Researchers have identified protein compounds that are potent inhibitors of the SARS-CoV-2 main protein, a key enzyme that enables the replication of the deadly virus. Their screening and synthetic chemistry approach was detailed in an article published March 3 in Angewandte Chemie. Read More
Combo of CRISPR, informatics helps uncover genetic regulators of immune cells
A new computational tool that uses CRISPR and multimodal single-cell sequencing data can provide insights into the function and regulation of human genes. The study, published in Nature Genetics on March 1, provides details on the molecular regulation of immune checkpoint inhibitors. Read More
Scientists achieve milestone in animal-free production of biologics
For the first time, scientists have successfully produced sugar-based biologic molecules utilizing bacteria, without the need for animal products. The paper, published in Nature Communications on March 2, describes the production of a common designer polysaccharide, chondroitin sulfate. Read More
Single-cell RNAseq differentiates cancer stem cells from healthy stem cells
Researchers have described a new single-cell RNA-sequencing approach, leveraging genomic and mitochondrial DNA mutations, that has the potential to differentiate normal stem cells from cancer stem cells. The article detailing the approach was published in Nature Communications on March 1. Read More
Janssen COVID-19 vaccine becomes 3rd authorized in U.S.
Janssen Biotech's COVID-19 vaccine has received an emergency use authorization from the U.S. Food and Drug Administration. The move allows the vaccine to be distributed in the U.S. for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 18 years of age or older. Read More
FDA committee gives nod to Janssen COVID-19 vaccine
A single-shot COVID-19 vaccine from Johnson & Johnson's Janssen Biotech subsidiary has received a positive recommendation from a U.S. Food and Drug Administration (FDA) advisory committee. Should the FDA grant the product emergency use authorization, the vaccine candidate will become the third to be made available in the U.S. Read More
New open-access toolkit helps research labs study SARS-CoV-2
One of the most important factors in fighting the COVID-19 pandemic is large-scale scientific collaborations and knowledge sharing. One international group of researchers has made its simple, robust toolkit available to laboratories around the globe that are unaccustomed to working with coronaviruses. The details can be found in a PLOS Biology paper published on February 25. Read More
Clinical pipeline promises effective 2nd-generation COVID-19 vaccines
Despite the small number of COVID-19 vaccines that have been granted emergency use authorizations by the U.S. Food and Drug Administration to date, many biopharmaceutical companies are continuing to push new vaccine candidates toward regulatory approval. The slow rollout of approved vaccines has created the need for second-generation products with the potential to accelerate the world's return to something approaching normalcy. Read More
Automated flow cytometry can expedite the discovery and development of next-gen drugs
Automated flow cytometry workflows outperform manual gated techniques by reducing variability among samples, while still achieving a high degree of accuracy. Automated workflows offer a number of advantages to pharmaceutical companies that can integrate them to accelerate drug discovery and development. Read More
New technique detects unique folding patterns in RNA of SARS-CoV-2
Scientists have developed a new technique for determining alternative structural RNA shapes of the SARS-CoV-2 virus. These self-regulatory segments of RNA, called switches, could serve as potential antiviral drug targets, according to a communication published in Nature Methods on February 22. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter